Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.

被引：2
|
作者：
Harrington, Kevin Joseph
Kong, Anthony
Mach, Nicolas
Chesney, Jason Alan
Castelo, Beatriz
Rischin, Danny
Cohen, Ezra E. W.
Radcliffe, Hoi-Shen
Gumuscu, Burak
Snyder, Wendy
Siu, Lillian L.
机构：
[1] Royal Marsden Inst Canc Res NIHR Biomed Res Ctr, London, England
[2] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England
[3] Univ Hosp Geneva, Dept Oncol, Geneva, Switzerland
[4] Univ Louisville, Brown Canc Ctr, Louisville, KY 40292 USA
[5] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain
[6] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[7] Univ Calif San Diego, San Diego, CA 92103 USA
[8] Amgen Inc, Uxbridge, Middx, England
[9] Merck & Co Inc, Kenilworth, NJ USA
[10] Amgen Inc, Thousand Oaks, CA 91320 USA
[11] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.6036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6036
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Bauman, J. E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy
    Harrington, K.
    Cohen, E.
    Siu, L.
    Rischin, D.
    Licitra, L.
    Vermorken, J.
    Le, Q. T.
    Tahara, M.
    Machiels, J. P.
    Hawk, N.
    Ge, J.
    Bidadi, B.
    Swaby, R.
    Burtness, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E43 - E44
  • [33] LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Siu, L. L.
    Burtness, B.
    Cohen, E. E.
    Harrington, K. J.
    Licitra, L. F.
    Rischin, D.
    Zhu, Y.
    Okpara, C. E.
    Pinheiro, C.
    Swaby, R. F.
    Machiels, J-P.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S684
  • [34] Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study
    Harrington, K.
    Kim, H. R.
    Salas, S.
    Oliva, M.
    Metcalf, R.
    Bernsdorf, M.
    Kim, J. W.
    Cohen, E.
    Siu, L. L.
    Rischin, D.
    Licitra, L.
    Vermorken, J.
    Le, Q. T.
    Tahara, M.
    Machiels, J. P.
    O'Hara, K.
    Pathiraja, K.
    Gumuscu, B.
    Bidadi, B.
    Burtness, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E42 - E42
  • [35] FIERCE-HN: A Multicenter, Randomized, Placebo-Controlled, Phase 3 Study of Ficlatuzumab plus Cetuximab in Pts W/ Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
    Bauman, J.
    Allman, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E734 - E734
  • [36] Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1epositive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial
    Fayette, J.
    Adkins, D. R.
    Psyrri, A.
    Siu, L. L.
    Tahara, M.
    William, W. Nassib, Jr.
    Pyle, R.
    Shen, Y-M.
    Zohren, F.
    Pennella, E.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S654 - S654
  • [37] FIERCE-HN: A Multicenter, Randomized, Placebo-controlled, Phase 3 Study of ficlatuzumab plus cetuximab in pts w/recurrent or Metastatic (R/M) HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
    Bauman, J.
    Allman, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E36 - E36
  • [38] Real-World Time on Treatment Analysis of Pembrolizumab Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients Stratified by ECOG PS in the United States
    Black, C.
    Wang, L.
    Ramakrishnan, K.
    Turzhitsky, V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E342 - E342
  • [39] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Argiris, Athanassios
    Li, Shuli
    Savvides, Panayiotis
    Forastiere, Arlene A.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345